eClinical Technology and Industy News

LJI and Charles River Laboratories to collaborate on COVID-19 research

New agreement paves the way for better mouse models to study how the human immune system fights SARS-CoV-2

Excerpt from the Press Release:

LA JOLLA, CA—Scientists at La Jolla Institute for Immunology (LJI) and Charles River Laboratories International, Inc., are launching a new project to uncover exactly how different cells in the human immune system respond to SARS-CoV-2, the virus that causes COVID-19. Their new research will allow scientists around the world to better capture how the body responds to the virus—from day one of infection.

The work at LJI will be led by Professor Sujan Shresta, Ph.D., a member of the LJI Center for Infectious Disease and Vaccine Research. Shresta’s laboratory will provide the first in-depth characterization of an ACE2ihumanized mouse model of SARS-CoV-2 infection, made available by Charles River in conjunction with Gempharmatech, LTD., including a close look at human immune responses. Her lab will be working closely with Kenneth Kim, Dipl. ACVP, director of the LJI Histopathology Core.

This new mouse model has been engineered to express human ACE2, the receptor that SARS-CoV-2 uses to infect human cells, and include the same immune cells made by the human body. As Shresta explains, these mice may give us a window into COVID-19 that we cannot get in human studies.

Researchers have found that the incubation period for SARS-CoV-2—the period when the disease is getting a foothold in the body but symptoms haven’t started yet—is usually four to five days. For severe cases, patients tend to show signs of the disease for 10 to 12 days before they are hospitalized. “At the time of hospitalization, people have already been infected for two weeks,” explains Kim.

“With human patients, we can only look at the immune response after there have been signs of infection,” adds Shresta. “So we need these animal models to understand the early time points in infection and get a window into the human immune response in tissues such as the lungs.”

The Shresta Lab will investigate how susceptible these mice are to SARS-CoV-2. The researchers will also measure viral loads in the mice and analyze lung tissues with help from the LJI Histopathology Core.

The goal for Charles River’s Research Model and Services business was to obtain and develop a model to solve the problem of understanding the role of human immune cells in early, acute SARS-CoV-2 infection. The best solution was to increase the susceptibility of the NCG mouse model, which is capable to be immuno-humanized, by engineering human ACE2 receptor (known now to be the receptor of many variant strains of SARS-COV-2) into the mouse ACE2 locus of NCG, named hACE2-NCG(1) leading to a scientific partnership and collaboration with Dr. Shresta’s lab to better define the utility of the model and to understand better mechanisms of early infection in a immuno-humanized mouse.

Click the button below to read the entire Press Release:

Continue Reading The Press Release

Discover What Sets TrialStat Apart From Ordinary Data Management

Click the image or button below to explore our interactive infographic which illustrates the comprehensive and unique capabilities of the TrialStat eClinical Suite.

Request Your Demo Today!

From rapid database build through database lock, we deliver consistent quality on-time and on-budget. Ready to upgrade your eClinical toolkit?

Archives